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DOI 10.1016/j.chembiol.2008.08.002When Dr. Thomas Starzl pioneered pedi-
atric liver transplants in the late 1960s at
the University of Colorado, the procedure
was controversial, as many children re-
jected their transplanted organs and died.
More kids started living longer as surgical
techniques and antirejection drugs im-
proved. While at the University of Pitts-
burgh Medical Center, Starzl and col-
leagues tested cyclosporine, an immune
suppressant developed from a fungus,
that radically reduced acute organ rejec-
tion. A decade later, they started using ta-
crolimus (FK506), also fungus derived,
which was up to 100 times more powerful
than cyclosporine but with fewer side
effects.
Like Odysseus deciding whether it was
better to have his sailors eaten or lose
his boat in the whirlpool when squeezed
between the monsters Scylla and Charyb-
dis, organ transplant recipients still face
unpleasant tradeoffs. Closely matched
donor organs are scarce; long-term use
of immunosuppressant drugs causes side
effects and can lead to infections and
cancer.
Over the years, however, Starzl and
other transplant researchers noticed that
certain patients seemed to exist in an im-
munological state of grace. They went off
immunosuppressants for various reasons
but didn’t reject their transplanted organs.
Indeed, in studies of selected groups of
patients who received organs from live
donors, around 1 in 5 could stop taking
immunosuppressants altogether or dra-
matically curtail their dosing with no ill
effect (Mazariegos et al., 1997; Margolis
and Turka, 2008).
The more closely an organ is HLA
(human leukocyte antigen) matched, the
better the chance of tolerance. Organs
from live donors, such as parents or sib-
lings, are better tolerated than those
from random deceased donors. Organ
condition and age matter as well.
Researchers want to be able to predict
tolerance, but no biomarkers exist to indi-
cate who will tolerate grafts. What sets the
naturally tolerant apart? Is it possible to
train the immune system to selectively
recognize an allograft without mounting
an inflammatory response?
Outgrowing Rescue Therapies
The concept of ‘‘immunological toler-
ance’’ can be traced back to the 1950s
and the skin graft work of Rupert Billing-
ham, Leslie Brent, and Sir Peter Medawar
(who received a Nobel Prize in 1960 for his
work with Sir Frank Macfarlane Burnet.)
Yet the field of tolerance in transplantation
is still inching its way forward. Better tools
and animal data promise progress. But
a driving force is that kids are growing
up with transplanted organs.
Dr. George Mazariegos, director of
Children’s Hillman Center for Pediatric
Transplantation and the Thomas E. Starzl
Transplantation Institute, notes that while
pediatric organ transplantation used to be
focused on ‘‘rescue therapies’’ to achieve
5 year survival, at this point, 5000 children
in the U.S. are living with transplants. ‘‘Now
we are seeing late-term morbidities,’’ said
Mazariegos. While transplanted organs in
children can now function for their lifespan,
immunosuppression affects growth, blood
pressure, kidney function, and tumor risk.
‘‘If we can lower it in children or eliminate
it, it would be a dramatic advance,’’ said
Mazariegos.
Liver transplantation patients seem to
achieve better tolerance, but only 1% of
pediatric liver patients can go off immuno-
suppressants entirely, Mazariegos esti-
mates. About 50 liver transplant patients
at Children’s Hospital have gone off
immunosuppressant drugs completely.
Others, after being initially stabilized, are
brought down to the lowest possible
dose; however, children who have HCV
or autoimmune disease are not good can-
didates for drug-weaning.
Building a Research Network
The UCSF-based Immune Tolerance Net-
work (ITN) (http://www.immunetolerance.
org) sponsors research groups around the
world that are developing predictive as-
says using genetic and immunological
markers as well as running trials using
different approaches to induce selective
tolerance. They hope to improve long-
term outcomes in organ transplants and
pave the way for better treatments for
T cell-mediated autoimmune conditions,
including type 1 diabetes, lupus, asthma,
and allergies. Founded in 1999 and
directed by Dr. Jeffrey Bluestone, the
Immune Tolerance Network currently
comprises around 40 institutions and is
supported by a $160 million, 7 year con-
tract with the National Institute for Allergy
and Infectious Diseases, the National
Institute for Diabetes and Digestive and
Kidney Diseases, and the Juvenile Diabe-
tes Research Foundation.
According to Vicki Seyfert-Margolis,
Ph.D., ITN chief scientific officer, the ITN
generally sponsors therapies in early
phase II with proof of safety and animal ef-
ficacy data that at least indicates biologi-
cal mechanisms relating to tolerance. So
far, therapies have focused primarily on
T cells; most are targeted at the process
involved in T cell activation or through
T cell depletion. Some antibody therapies
such as nonmitogenic anti-CD3s and
CTLA4Ig are seeing dual use for trans-
plant and autoimmune conditions. Addi-
tionally, attention is being paid to B cells,
resulting in a study using rituxumab for
depletion of B cells in mice as well as to
an exploration of alloantibodies (which
develop in the recipient in response to
grafts and spur rejection) and combining
T cell-targeted therapies with rituximab.
‘‘I’d not say that anything has emerged
as a clear winner here,’’ said Seyfert-
Margolis.
Over the years, however, Starzl and other transplant researchers
noticed that certain patients seemed to exist in an immunological
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Their Meds
Although the ITN advises kidney transplant
recipients not to stop immunosuppressant
medications without medical supervision,
they are actively looking for people who,
for whatever reason, managed to do just
that and keep their transplanted organs.
Dr. Kenneth Newell, associate professor
of surgery at Emory University, is compil-
ing the ITN Registry of Tolerant Kidney
Transplant Patients. The U.S. registry col-
lects blood and tissue samples looking for
genetic and immunological insight into
what makes their immune systems unique.
Finding the innately tolerant takes ingenu-
ity: one productive strategy was an adver-
tisement in Alaska Airlines magazine. So
far, the registry has enrolled 25 people
and Newell’s study has enrolled 171 par-
ticipants, including those in additional
comparison study groups.
The ITN is currently sponsoring 12 active
studies and several more in development.
One example is an ongoing prospective
phase II trial under the supervision of Dr.
Avraham Shaked, director of the PENN
Transplantation Center, which involves
weaning a projected 275 adults with liver
transplants (some with HCV) from medica-
tion. The study is comparing immune and
genetic profiles of HCV-infected trans-
plant recipients as well as examining the
use of T cell depletion with Campath-1H
(alemtuzumab, a humanized anti-CD52
monoclonal antibody). Another multicen-
ter study is weaning adult kidney trans-
plant recipients off immunosuppressants.
ITN-sponsored trials also include studies
in mixed chimerism in kidney transplants
(David Sachs and Benedict Cosimi, as well
as Megan Sykes at Massachusetts General
Hospital), use of Campath-1H/Rapamycin
in kidney transplantation (Stuart Knechtle
at the University of Wisconsin Medical
School), and a kidney transplant weaning
trial of LEA29Y (Flavio Vincenti, University
of California, San Francisco, and Christian
Larsen at the Emory Transplant Center).
‘‘Costimulation blockade implies block-
ing those molecular pathways that are
important in instigating T cell-mediated
immune responses,’’ Thomson said.
‘‘Such strategies have proved highly
effective in small animal models, not so
effective in nonhuman primates.’’ Thom-
son said costimulation blockade is still752 Chemistry & Biology 15, August 25, 200promising as an adjunctive immunosup-
pressive therapy. The CD40/CD40 ligand
pathway has received the most attention,
but initial clinical testing of an anti-CD40
ligand monoclonal antibody was curtailed
because of blood clots.
One technique is to deplete patients’
immune systems before transplantation
in order to minimize immunosuppressants
afterwards. At Pittsburgh, researchers use
Campath 1H to deplete peripheral T cells
and B cells in pediatric kidney patients
prior to transplantation, then lower the
dose of immunosuppressants afterwards.
Creating Chimeras
Another technique that is closer to achiev-
ing true tolerance is inducing ‘‘mixed chi-
merism’’ based on blending donor and re-
cipient immune systems. In January 2008,
Dr. David Sachs and colleagues at Massa-
chusetts General Hospital reported results
of a trial of 5 kidney transplant patients be-
tween 22 and 46 years of age. Their kid-
neys came from parents or siblings but
were immunologically mismatched.
Sachs’ team ablated their immune sys-
tems with radiation and chemotherapy
and depleted their T cells with drugs.
They then transplanted the donor kidneys
along with an infusion of bone marrow cells
isolated from the recipient. ‘‘Over the first
few weeks the patients are rather immuno-
suppressed, but when their immune sys-
tem does come back, it comes back
tolerant to the recipient as well as to the do-
nor, but not to anything else,’’ said Sachs.
‘‘Not to third party. Not to bacteria. Not to
viruses. So you are left with a much better
immune system than you would have on
immunosuppressive drugs.’’ The doctors
stopped the drugs after 9–12 months.
Two-to-five years later, four patients still
didn’t need immunosuppressants. The
fifth patient rejected the kidney, possibly
sensitized by prior exposure. He success-
fully received a second kidney transplant
on standard immunosuppression.
‘‘What you are doing is trading an up-
front more difficult and potentially danger-
ous procedure for a lifetime not having to
be on immunosuppressive drugs,’’ Sachs
said. ‘‘Even if patients take their drugs
properly, we haven’t been able to stop
chronic rejection.’’ According to Sachs,
chronic rejection claimsabout5% of organ8 ª2008 Elsevier Ltd All rights reservedtransplants a year. ‘‘We are hoping that tol-
erance will avoid that as well,’’ Sachs said.
According to Sachs, in their animal stud-
ies, monkeys have not shown chronic re-
jection in 10 years. The next steps are to re-
produce these results in more patients and
to study the use of unrelated donors and,
hopefully, deceased donors.
Inhabiting an Immunological State
of Grace
Amy Whitacre, an ebullient 29 year old ar-
chitect in Ohio, lives in a state of immuno-
logic grace. She is the elusive key to the
mystery of tolerance. When Whitacre
was 6 months old, her parents noticed
something was wrong. They took their
baby from doctor to doctor. Eventually,
she was diagnosed with idiopathic cirrho-
sis of the liver. Her liver swelled patholog-
ically, putting pressure on her aorta and
creating varices—abnormally enlarged
veins in the lower part of her esophagus.
Doctors feared they would rupture and
she would bleed to death. Whitacre re-
called an otherwise normal childhood,
but she couldn’t go out and play because
she had to take phenobarbitol at night.
In 1987, when she turned 8 and before
her liver failed, Dr. Thomas Starzl trans-
planted a new liver into her at Children’s
Hospital of Pittsburgh. ‘‘I’ve been very
lucky and never went into any sort of re-
jection,’’ Whitacre said. As she grew, her
doses of cyclosporine, antibiotics, and
steroids became more infrequent. ‘‘It got
to the point that I was taking my meds
on Tuesdays and Thursdays my last year
in college,’’ Whitacre said. Her doctors
(Mazariegos among them) biopsied her
liver and periodically checked her blood.
Whitacre has been immunosuppressant
free for 7 years. She periodically partici-
pates in studies run by Mazariegos. ‘‘I
hope there is something about me that
can help others,’’ Whitacre said.
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